DK177330B1 - Konstruktion af c-dna af alfavirus af salmonider - Google Patents
Konstruktion af c-dna af alfavirus af salmonider Download PDFInfo
- Publication number
- DK177330B1 DK177330B1 DKPA200600811A DKPA200600811A DK177330B1 DK 177330 B1 DK177330 B1 DK 177330B1 DK PA200600811 A DKPA200600811 A DK PA200600811A DK PA200600811 A DKPA200600811 A DK PA200600811A DK 177330 B1 DK177330 B1 DK 177330B1
- Authority
- DK
- Denmark
- Prior art keywords
- alphavirus
- sequence
- recombinant
- nucleotides
- dna
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title claims abstract description 65
- 108091028026 C-DNA Proteins 0.000 title claims description 37
- 241000277331 Salmonidae Species 0.000 title claims description 30
- 238000010276 construction Methods 0.000 title description 11
- 239000002299 complementary DNA Substances 0.000 title 1
- 125000006850 spacer group Chemical group 0.000 claims abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 46
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 108020004511 Recombinant DNA Proteins 0.000 claims description 23
- 101710172711 Structural protein Proteins 0.000 claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000010367 cloning Methods 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 238000005538 encapsulation Methods 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 3
- 239000000556 agonist Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 61
- 241000700605 Viruses Species 0.000 description 47
- 208000015181 infectious disease Diseases 0.000 description 26
- 230000002458 infectious effect Effects 0.000 description 21
- 239000012634 fragment Substances 0.000 description 17
- 108060001084 Luciferase Proteins 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 14
- 238000001890 transfection Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 235000019688 fish Nutrition 0.000 description 11
- 241000251468 Actinopterygii Species 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 7
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101800000515 Non-structural protein 3 Proteins 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108010046722 Thrombospondin 1 Proteins 0.000 description 3
- 102100036034 Thrombospondin-1 Human genes 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 101150066002 GFP gene Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 101800000514 Non-structural protein 4 Proteins 0.000 description 2
- 241000277275 Oncorhynchus mykiss Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101150102573 PCR1 gene Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 101100326757 Drosophila melanogaster Capr gene Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101800000511 Non-structural protein 2 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 241000277269 Oncorhynchus masou Species 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 101800000980 Protease nsP2 Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000316146 Salmo trutta trutta Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 102200149503 rs121909051 Human genes 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0506275 | 2005-06-21 | ||
| FR0506275A FR2887259B1 (fr) | 2005-06-21 | 2005-06-21 | CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200600811A DK200600811A (da) | 2006-12-22 |
| DK177330B1 true DK177330B1 (da) | 2013-01-14 |
Family
ID=35809739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA200600811A DK177330B1 (da) | 2005-06-21 | 2006-06-15 | Konstruktion af c-dna af alfavirus af salmonider |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8603491B2 (https=) |
| EP (1) | EP1907535B1 (https=) |
| JP (1) | JP5284086B2 (https=) |
| AU (1) | AU2006260796B2 (https=) |
| CA (1) | CA2612362C (https=) |
| DK (1) | DK177330B1 (https=) |
| FR (1) | FR2887259B1 (https=) |
| NO (1) | NO342179B1 (https=) |
| WO (1) | WO2006136704A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2887259B1 (fr) * | 2005-06-21 | 2007-09-14 | Agronomique Inst Nat Rech | CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES |
| CL2015002907A1 (es) * | 2015-09-29 | 2016-06-17 | Univ Santiago Chile | Vacuna oral contra isav que comprende nanopartículas de quitosán que encapsulan una virina del virus isa y nanoparticulas de quitosán que encapsulan un adyuvante que consiste en un adn que se codifica para la replicasa/transcriptasa de un alfavirus de salmón (replicón), proceso de preparación, método para tratar peces infectados con isav y método para estimular la respuesta inmune en peces. |
| JP2019511255A (ja) | 2016-01-11 | 2019-04-25 | バーンダリ，インク． | マイクロニードル組成物およびそれを使用する方法 |
| NO344938B1 (en) * | 2018-12-13 | 2020-07-20 | Patogen As | Pancreas Disease Virus Markers |
| EP3693465A1 (en) * | 2019-02-05 | 2020-08-12 | Pharmaq AS | Novel fish coronavirus |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994001549A1 (fr) * | 1992-07-02 | 1994-01-20 | Sankyo Company, Limited | Ribozyme bouclee en epingle a cheveux |
| SE9401091D0 (sv) * | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| CA2303768C (en) * | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| EP1075523B1 (en) * | 1998-05-08 | 2007-08-08 | Intervet International BV | Structural proteins of fish pancreatic disease virus and uses thereof |
| MXPA03001680A (es) * | 2000-08-29 | 2004-11-01 | Wyeth Corp | Empaque de particulas de un replicon del virus de acido ribonucleico (arn) de hebra positiva. |
| EP1540004A4 (en) * | 2002-07-31 | 2007-10-03 | Nucleonics Inc | DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| FR2887259B1 (fr) * | 2005-06-21 | 2007-09-14 | Agronomique Inst Nat Rech | CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES |
-
2005
- 2005-06-21 FR FR0506275A patent/FR2887259B1/fr not_active Expired - Lifetime
-
2006
- 2006-06-15 DK DKPA200600811A patent/DK177330B1/da active
- 2006-06-21 US US11/993,676 patent/US8603491B2/en active Active
- 2006-06-21 AU AU2006260796A patent/AU2006260796B2/en active Active
- 2006-06-21 WO PCT/FR2006/001405 patent/WO2006136704A2/fr not_active Ceased
- 2006-06-21 EP EP06778633A patent/EP1907535B1/fr active Active
- 2006-06-21 CA CA2612362A patent/CA2612362C/fr active Active
- 2006-06-21 JP JP2008517535A patent/JP5284086B2/ja active Active
-
2007
- 2007-12-17 NO NO20076452A patent/NO342179B1/no unknown
-
2010
- 2010-07-01 US US12/828,739 patent/US20110064767A1/en not_active Abandoned
-
2013
- 2013-10-18 US US14/057,328 patent/US9611300B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2887259B1 (fr) | 2007-09-14 |
| US20080317777A1 (en) | 2008-12-25 |
| US8603491B2 (en) | 2013-12-10 |
| CA2612362A1 (fr) | 2006-12-28 |
| DK200600811A (da) | 2006-12-22 |
| WO2006136704A2 (fr) | 2006-12-28 |
| FR2887259A1 (fr) | 2006-12-22 |
| CA2612362C (fr) | 2013-10-29 |
| JP5284086B2 (ja) | 2013-09-11 |
| US20110064767A1 (en) | 2011-03-17 |
| US9611300B2 (en) | 2017-04-04 |
| EP1907535B1 (fr) | 2012-09-12 |
| US20140242114A1 (en) | 2014-08-28 |
| NO342179B1 (no) | 2018-04-09 |
| AU2006260796A1 (en) | 2006-12-28 |
| AU2006260796B2 (en) | 2010-10-28 |
| WO2006136704A3 (fr) | 2007-03-15 |
| NO20076452L (no) | 2008-03-07 |
| JP2008546399A (ja) | 2008-12-25 |
| EP1907535A2 (fr) | 2008-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casais et al. | Reverse genetics system for the avian coronavirus infectious bronchitis virus | |
| Kuhn et al. | Infectious RNA transcripts from Ross River virus cDNA clones and the construction and characterization of defined chimeras with Sindbis virus | |
| Fischer et al. | Analysis of a recombinant mouse hepatitis virus expressing a foreign gene reveals a novel aspect of coronavirus transcription | |
| Pierro et al. | Development of an orally infectious Sindbis virus transducing system that efficiently disseminates and expresses green fluorescent protein in Aedes aegypti | |
| KR20090008193A (ko) | 가감염성 플라비바이러스 및 이들의 용도 | |
| Kulasegaran-Shylini et al. | The 5′ UTR-specific mutation in VEEV TC-83 genome has a strong effect on RNA replication and subgenomic RNA synthesis, but not on translation of the encoded proteins | |
| US7332322B2 (en) | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof | |
| Volkova et al. | IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells | |
| Hill et al. | RNA-RNA recombination in Sindbis virus: roles of the 3'conserved motif, poly (A) tail, and nonviral sequences of template RNAs in polymerase recognition and template switching | |
| Kamrud et al. | Alphavirus replicon approach to promoterless analysis of IRES elements | |
| Higgs et al. | Viral expression systems and viral infections in insects | |
| US9611300B2 (en) | cDNA construct of Salmonidae alphavirus | |
| RU2307872C2 (ru) | НОВАЯ ПОЛНОРАЗМЕРНАЯ ГЕНОМНАЯ PHK ВИРУСА ЯПОНСКОГО ЭНЦЕФАЛИТА, ПОЛУЧЕННАЯ ИЗ НЕЕ ИНФЕКЦИОННАЯ кДНК JEV И ИХ ПРИМЕНЕНИЕ | |
| Michel et al. | Adaptation of Venezuelan equine encephalitis virus lacking 51-nt conserved sequence element to replication in mammalian and mosquito cells | |
| Tzeng et al. | Rubella virus DI RNAs and replicons: requirement for nonstructural proteins acting in cis for amplification by helper virus | |
| Rausalu et al. | Properties and use of novel replication-competent vectors based on Semliki Forest virus | |
| CN101225395A (zh) | 亚洲一型口蹄疫病毒感染性cDNA及其构建方法 | |
| ES2268797T3 (es) | Vectores alvirus. | |
| Spadaccini et al. | Stable expression of a foreign protein by a replication-competent rubella viral vector | |
| Binder et al. | Genetic stability of attenuated mengovirus vectors with duplicate primary cleavage sequences | |
| Konduru et al. | Hepatitis A virus (HAV) packaging size limit | |
| CA2238660A1 (en) | Gene sequences of rubella virus associated with attenuation | |
| Wang et al. | Rescue of rubella virus replication-defective mutants using vaccinia virus recombinant expressing rubella virus nonstructural proteins | |
| CN121801963A (zh) | 恩杜牧病毒全长感染性克隆、复制子系统及其制备和应用 | |
| Tzeng | Studies on rubella virus RNA synthesis and DI RNA replication |